natgillin/translations-raw huggingface dataset:
At 144 weeks in the open-label phase of SINGLE, virologic suppression was maintained, the DTG +ABC/3TC arm (71%) was superior to the EFV/TDF/FTC arm (63%), treatment difference was 8.3% (2.0, 14.6).
U 144. tjednu otvorene faze ispitivanja SINGLE, virološka supresija bila je održana, DTG + ABC/3TC skupina (71%) bila je superiorna u odnosu na EFV/TDF/FTC skupinu (63%), razlika između liječenja bila je 8,3% (2,0; 14,6).
At 144 weeks, the proportion of patients with HIV-1 RNA below 400 copies/ml and 50 copies/ml was 71% and 68% respectively in the tenofovir disoproxil 245 mg (as fumarate) arm, compared to 64% and 63% in the stavudine arm.
U 144. tjednu, udio pacijenata s HIV-1 RNK manjom od 400 kopija/ml odnosno 50 kopija/ml bio je 71%, odnosno 68% u skupini liječenoj s 245 mg tenofovirdisoproksila (u obliku tenofovirdizoproksilfumarata) u usporedbi sa 64% odnosno 63% u skupini liječenoj stavudinom.
At 2 years post- treatment, 16% (6 of 38) of patients remained 15 percentiles or more below their baseline weight curve and 11% (4 of 38) remained 15 percentiles or more below their baseline height curve.
Dvije godine nakon liječenja 16% (6 od 38) bolesnika ostalo je 15 percentila ili više ispod početne krivulje tjelesne težine, a 11% (4 od 38) njih je ostalo 15 percentila ili više ispod početne krivulje visine.
At 2 years, the cumulative incidence of NRM was 11.3% (95%CI, 5.5-19.3%), and that of relapse or progression from allo-HCT was 43.8% (95CI, 31.1-55.7%).
Nakon 2 godine, ukupna incidencija smrtnosti koja nije povezana s relapsom iznosila je 11,3% (95%- tni CI, 5,5 - 19,3%), a ona od relapsa ili progresije od alogenog HCT-a iznosila 43,8% (95%-tni CI, 31,1
At 2 years, the cumulative incidence of NRM was 11.3% (95%CI, 5.5-19.3%), and that of relapse or progression from allo-HCT was 43.8% (95CI, 31.1-55.7%).
Nakon 2 godine, ukupna incidencija smrtnosti koja nije povezana s relapsom iznosila je 11,3% (95%-tni CI, 5,5 - 19,3%), a ona od relapsa ili progresije od alogenog HCT-a iznosila 43,8% (95%-tni CI, 31,1 - 55,7%).
At 2 years1
U 2. godini1
At 20 minutes post-injection, 75% of the radioactivity in plasma was present as polar metabolites.
Dvadeset minuta nakon primjene, 75% radioaktivnosti u plazmi bilo je prisutno u obliku polarnih metabolita.
At 208 weeks
208. tjedan
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone.
U 24 sata, razine sildenafila u plazmi bile su još uvijek približno 200 ng/ml u usporedbi s približno 5 ng/ml kada se sildenafil davao zasebno.
At 24 months
U 24. mjesecu
At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with zoledronic acid as compared to the effects observed in post- menopausal women in the HORIZON-PFT study.
Nakon 24 mjeseca zapaženo je slično značajno povećanje od 3,6% BMD-a cijelog kuka u bolesnika liječenih zoledronatnom kiselinom u usporedbi s učincima zapaženima u žena u postmenopauzi u ispitivanju HORIZON-PFT.
At 24 months, estimates for overall survival were 68.2 % in the R-CHOP arm compared to 57.4 % in the CHOP arm.
24 mjeseca procjene ukupnog preživljenja iznosile su 68,2% za R-CHOP skupinu, odnosno 57,4% za CHOP skupinu.
At 24 monthsb
U 24. mjesecub
At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA < 50 copies/ml.
Nakon 24 tjedna iza randomizacije, u ispitivanju TRANxITION, 92,6 % bolesnika na Viramuneu 200 mg s trenutnim oslobađanjem dvaput dnevno odnosno 93,6 % bolesnika na Viramuneu 400 mg s produljenim oslobađanejm jednom dnevno , i dalje je imalo HIV-1 RNK vrijednosti < 50 kopija/ml.
At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA < 50 copies/ml.
Nakon 24 tjedna iza randomizacije, u ispitivanju TRANxITION, 92,6 % bolesnika na Viramuneu 200 mg s trenutnim oslobađanjem dvaput dnevno odnosno 93,6 % bolesnika na Viramuneu 400 mg s produljenim oslobađanjem jednom dnevno, i dalje je imalo HIV-1 RNK vrijednosti < 50 kopija/ml.
At 24 weeks, 16 of 23 (70%) adolescents (12 to less than 18 years of age) treated with Tivicay once daily (35 mg n=4, 50 mg n=19) plus OBR achieved viral load <50 copies/mL.
Nakon 24 tjedna, 16 od 23 (70%) adolescenata (u dobi od 12 do manje od 18 godina) liječenih lijekom Tivicay jedanput na dan (35 mg n=4, 50 mg n=19) u kombinaciji s optimiziranim osnovnim režimom liječenja postiglo je virusno opterećenje od < 50 kopija/ml.
At 24 weeks, 56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of placebo- treated patients.
Nakon 24 tjedna, 56% bolesnika u grupi liječenoj Enbrelom postiglo je PASI 75 u usporedbi s 5% u skupini na placebu.
At 24 weeks, 56% of patients in the etanercept-treated group had achieved the PASI 75 compared to 5% of placebo- treated patients.
Nakon 24 tjedna, 56% bolesnika u skupini liječenoj etanerceptom postiglo je PASI 75 u usporedbi s 5% u skupini koja je primala placebo.
At 24 weeks, reductions in serum uric acid concentrations ranged from –48.3 to –18.3 micromoles/l (–0.87 to –0.33 mg/dl).
U 24. tjednu se smanjenje koncentracije mokraćne kiseline u serumu kretalo između -48,3 i -18,3 mikromola/l (-0,87 do -0,33 mg/dl).
At 24 weeks, the difference in rates between treatment groups represented a 34% (rate ratio 0.662, p = 0.047) decrease relative to placebo for omalizumab patients.
U 24. tjednu razlika u stopama između terapijskih skupina bila je 34%- tno smanjenje (omjer stopa 0,662, p=0,047) kod bolesnika liječenih omalizumabom u odnosu na placebo.
At 240-weeks, in treatment-naïve patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 22 %, 44 % and 17 %, respectively, of co-infected subjects treated with ISENTRESS as compared to 13 %, 13 % and 5 % of all other subjects treated with ISENTRESS.
Nakon 240 tjedana su, u bolesnika koji do tada nisu bili liječeni, odstupanja u laboratorijskim nalazima AST-a, ALT-a i ukupnog bilirubina 2. ili višeg stupnja koja su predstavljala pogoršanje u odnosu na početne vrijednosti zabilježena u 22%, 44% odnosno 17% ispitanika s istodobnom infekcijom koji su liječeni lijekom ISENTRESS, u odnosu na 13%, 13% odnosno 5% svih ostalih ispitanika liječenih lijekom ISENTRESS.
At 240-weeks, in treatment-naïve patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 22 %, 44 % and 17 %, respectively, of co-infected subjects treated with raltegravir as compared to 13 %, 13 % and 5 % of all other subjects treated with raltegravir.
Nakon 240 tjedana su, u bolesnika koji do tada nisu bili liječeni, odstupanja u laboratorijskim nalazima AST-a, ALT a i ukupnog bilirubina 2. ili višeg stupnja koja su predstavljala pogoršanje u odnosu na početne vrijednosti zabilježena u 22%, 44% odnosno 17% ispitanika s istodobnom infekcijom koji su liječeni raltegravirom, u odnosu na 13%, 13% odnosno 5% svih ostalih ispitanika liječenih raltegravirom.
At 250 mg/kg/day, fetal malformations included limb anomalies (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia); moderate dilation of the lateral ventricle in the brain; abnormal placement of the right subclavian artery; absent intermediate lobe in the lungs; low- set kidney; altered liver morphology; incompletely or not ossified pelvis; an increased average for supernumerary thoracic ribs and a reduced average for ossified tarsals.
250 mg/kg na dan, fetalne malformacije uključivale su anomalije udova (savijeni i/ili rotirani prednji i stražnji udovi, nespojeni ili odsutni prst) i s time povezane malformacije kostura (neosificirane metakarpalne kosti, neporavnate falangealne i metakarpalne kosti, odsutnost prsta, neosificirane falange i kratka neosificirana ili svijena tibija), umjereno proširena lateralna moždana komora; abnormalna lokalizacija desne arterije supklavije; odsutnost srednjeg režnja pluća; nisko postavljen bubreg; promijenjena morfologija jetre; nepotpuno osificirane ili neosificirane zdjelične kosti; povišen prosječni broj prekobrojnih torakalnih rebara i smanjen prosječni broj osificiranih tarzalnih kostiju.
At 26 weeks
U 26. tjednu
At 28 weeks, treatment with once weekly Trulicity 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo and a significantly greater percentage of patients achieving HbA1c targets of < 7.0 % and ≤ 6.5 % (Table 8).
U 28. tjednu, liječenje lijekom Trulicity 1,5 mg jedanput na dan dovelo je do statistički značajnog smanjenja razine HbA1c u usporedbi s placebom te značajno većeg postotka bolesnika koji su postigli ciljnu vrijednost HbA1c od < 7,0% i ≤ 6,5% (Tablica 8).
At 3 months, the incidence of iris hyperpigmentation with bimatoprost 0.3 mg/mL single dose was 0.3%.
Nakon 3 mjeseci primjene jednodoznog bimatoprosta 0,1 mg/ml incidencija hiperpigmentacije šarenice bila je 0,3%).
At 3 years (week 148), 82% of patients re-randomised to maintenance treatment were PASI 75 responders.
U 3. godini (148. tjedan), 82% bolesnika koji su ponovno randomizirani na održavanje liječenja, imalo je odgovor PASI 75.
At 3 years, LEMTRADA reduced the risk of 6-month SAD by 76% (hazard ratio 0.24 [95% CI: 0.110, 0.545], p<0.0006) and reduced the ARR by 67% (rate ratio 0.33 [95% CI: 0.196, 0.552], p<0.0001) as compared to subcutaneous IFNB-1a.
Nakon 3 godine LEMTRADA je smanjila rizik od 6-mjesečnog SAD-a za 76% (omjer hazarda 0,24 [95% CI: 0,110, 0,545], p<0,0006) i ARR-a za 67% (omjer udjela 0,33 [95% CI: 0,196, 0,552], p<0,0001) u usporedbi sa supkutano primijenjenim IFNB-1a.
At 30 and 60 minutes, significant elimination of midazolam has already occurred and therefore the increase in mean Cmax is less pronounced; 1.3 to 1.6 and 1.2 to 1.5 fold respectively. (see section 4.2).
Nakon 30 i 60 minuta, značajna eliminacija midazolama već se dogodila pa je stoga porast srednje vrijednosti Cmax mnogo manje izražen: 1,3 do 1,6 puta nakon 30 minuta i 1,2 do 1,5 puta nakon 60 minuta (vidjeti dio 4.2).
At 36 month follow-up, the GMT in girls (2 doses, n=86) remained non-inferior to the GMT in women (3doses, n=86) for all 4 HPV types.
Nakon 36 mjeseci praćenja, GMT u djevojčica (2 doze, n=86) ostao je neinferioran GMT-u u žena (3 doze, n=86) za sva 4 tipa HPV-a.
At 36 months
U 36. mjesecu
At 4 hours post first dose, there was a significant difference in the mean percentage change from baseline plasma uric acid concentration (p <0.0001) in the Fasturtec group (- 86.0%) compared to that for the allopurinol group (-12.1%).
4 sata nakon primjene prve doze zabilježena je značajna razlika u prosječnom postotku promjene koncentracije mokraćne kiseline u plazmi u odnosu na početnu (p < 0,0001) u skupini koja je primala Fasturtec (-86,0%), u usporedbi sa skupinom koja je primala alopurinol (-12,1%).
At 48 months
U 48. mjesecu
At 48 months, there was a statistically significant difference in graft survival in favour of the Rapamune following ciclosporin elimination group compared to the Rapamune with ciclosporin therapy group (including and excluding loss to follow-up).
Nakon 48 mjeseci opažena je statistički značajna razlika u preživljenju presatka u korist skupine liječene Rapamuneom nakon uklanjanja ciklosporina u usporedbi sa skupinom liječenom Rapamuneom i ciklosporinom (uključujući i isključujući bolesnike izgubljene iz praćenja).
At 48 weeks of treatment the emtricitabine-containing regimen demonstrated an equivalent proportion of patients with HIV RNA < 400 copies/ml (94% emtricitabine versus 92%) and a greater proportion of patients with HIV RNA < 50 copies/ml (95% emtricitabine versus 87%) compared with the patients continuing with their PI-HAART regimen.
Nakon 48 tjedana terapije, terapija emtricitabinom je pokazala ekvivalentan udio pacijenata s HIV RNK < 400 kopija/ml (94% u skupini emtricitabina naspram 92% u PI-HAART) te veći udio pacijenata s HIV RNK < 50 kopija/ml (95% za emtricitabin naspram 87% za PI-HAART) u usporedbi s pacijentima koji su nastavili terapiju PI-HAART-om.
At 48 weeks these rates were 25.2% of patients in the tipranavir with ritonavir arm and 15.6% in the comparator arm.
Nakon 48 tjedana ove stope su bile 25,2% bolesnika na režimu tipranavir s ritonavirom te 15,6% u komparatorskom režimu.
At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA < 50 copies/mL with the once and twice daily regimens of lopinavir/ritonavir, respectively.
U 48. tjednu je 70% odnosno 64% pacijenata pokazalo HIV-1 RNK < 50 kopija/mL uz režim doziranja lopinavira/ritonavira jedanput odnosno dvaput na dan.
At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults.
U 48. tjednu, njih 92% (46/50) postiglo je HIV-1 RNK < 50 kopija/ml, što je slično stopama odgovora u ispitivanjima odraslih bolesnika zaraţenih virusom HIV-1 koji prethodno nisu bili liječeni.
At 48 weeks, the difference for dapagliflozin as add-on to metformin plus sitagliptin compared with placebo was -2.07 kg.
U 48. tjednu, razlika kod primjene dapagliflozina kao dodatka metforminu i sitagliptinu u usporedbi s placebom iznosila je
At 48 weeks, the difference for dapagliflozin as add-on to sitagliptin (with or without metformin) compared with placebo was -2.22 kg.
U 48. tjednu, razlika za dapagliflozin kao dodatak sitagliptinu (sa ili bez metformina) u usporedbi s placebom je bila -2,22 kg.
At 48-weeks in Phase III trials, rash of various types was observed in 15.5% males and 20.5% females receiving Aptivus co- administered with low dose ritonavir.
Nakon 48 tjedana, u ispitivanjima faze III, različiti tipovi osipa opaženi su u 15,5% muškaraca i 20,5% žena koji su dobivali Aptivus s niskom dozom ritonavira.
At 48-weeks, a higher proportion of patients receiving tipranavir with ritonavir achieved a treatment response in comparison to the comparator protease inhibitor/ritonavir for nearly all of the possible combinations of genotypic resistance mutations (see table below).
U 48 tjedana, veći je broj bolesnika na tipranaviru s ritonavirom postigao reakciju na liječenje u usporedbi s kontrolnom skupinom liječenom inhibitorom proteaze s ritonavirom za gotovo sve moguće kombinacije genotipskih mutacija povezanih s rezistencijom (vidjeti tablicu u nastavku).
At 5 years (week 244), 80% of patients re-randomised to maintenance treatment were PASI 75 responders.
U 5. godini (244. tjedan), 80% bolesnika koji su ponovno randomizirani na održavanje liječenja imalo je PASI odgovor 75.
At 5 years following initiation of a 0, 1, 6 month schedule of Twinrix Paediatric in children aged 1-11 years all subjects followed up retained ≥15 mIU/ml anti-HAV antibody and 97% had anti-HBs antibody ≥10 mIU/ml.
U 5 godina nakon uvođenja rasporeda cijepljenja od 0, 1, 6 mjeseci cjepivom Twinrix Paediatric kod djece u dobi od 1 do 11 godina, svi praćeni ispitanici zadržali su anti-HAV protutijela ≥15 mIU/ml, dok ih je 97% zadržalo anti-HBs protutijela ≥10 mIU/ml.
At 5 years, LEMTRADA reduced the risk of SAD by 69% (hazard ratio 0.31 [95% CI: 0.161, 0.598], p=0.0005) and reduced the ARR by 66% (rate ratio 0.34 [95% CI: 0.202, 0.569], p<0.0001) as compared to subcutaneous IFNB-1a.
Nakon 5 godina LEMTRADA je smanjila rizik od SAD-a za 69% (omjer hazarda 0,31 [95% CI: 0,161, 0,598], p=0,0005) i ARR-a za 66% (omjer udjela 0,34 [95% CI: 0,202, 0,569], p<0,0001) u usporedbi sa supkutano primijenjenim IFNB-1a.
At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p<0.001).
U 54. je tjednu klinički odgovor imalo 44,9% bolesnika u objema skupinama liječenima infliksimabom, u odnosu na 19,8% ispitanika u skupini koja je primala placebo (p < 0,001).
At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p<0.001).
U 54. je tjednu klinički odgovor imalo 44,9% bolesnika u objema skupinama liječenima infliksimabom, u odnosu na19,8% ispitanika u skupini koja je primala placebo (p < 0,001).
At 6 months
Nakon 6 mjeseci
At 6 months after the last dose, the median reductions in B cell counts were >99% for ofatumumab in combination with chlorambucil and 94% for chlorambucil alone.
Šest mjeseci nakon posljednje doze medijan smanjenja broja B-stanica iznosio je > 99% za ofatumumab u kombinaciji s klorambucilom te 94% za monoterapiju klorambucilom.
At 6 months, in the active-controlled, randomised, double-blind, multicenter, non-inferiority trial, in the MabThera group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline, had low IgA, IgG and IgM levels, respectively compared to 25%, 50% and 46% in the cyclophosphamide group.
U randomiziranom, dvostruko slijepom, multicentričnom, aktivnim lijekom kontroliranom ispitivanju neinferiornosti su nakon 6 mjeseci u skupini koja je primala lijek MabThera vrijednosti IgA, IgG i IgM bile snižene u 27%, 58% odnosno 51% bolesnika koji su na početku ispitivanja imali normalne vrijednosti imunoglobulina, u usporedbi s 25%, 50% odnosno 46% bolesnika u skupini koja je primala ciklofosfamid.
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44 %) (chi-square p = 0.019).
6 mjeseci je udio bolesnika koji su preživjeli bio značajno veći u skupini bolesnika koji su primali TMZ (60 %) nego u skupini bolesnika koji su primali prokarbazin (44 %) (hi-kvadrat p = 0,019).
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44 %) (chi-square p=0.019).
Nakon 6 mjeseci je udio bolesnika koji su preživjeli bio značajno veći u skupini bolesnika koji su primali TMZ (60%) nego u skupini bolesnika koji su primali prokarbazin (44%) (hi-kvadrat p = 0,019).
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44%) (chi-square p = 0.019).
Nakon 6 mjeseci je udio bolesnika koji su preživjeli bio značajno veći u skupini bolesnika koji su primali TMZ (60%) nego u skupini bolesnika koji su primali prokarbazin (44%) (hi-kvadrat p = 0,019).
At 60 months
U 60. mjesecu
At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), AST, C-reactive protein (CRP) and myoglobin levels.
Pri dozi od 600 mg u jednog je ispitanika došlo do edema stopala i šaka te porasta razina kreatin fosfokinaze (CPK), AST, C- reaktivnog proteina (CRP) i mioglobina.
At 7 days after the booster dose, 98%-100% of subjects who previously received Menveo and 73%-84% of subjects who previously received ACWY-PS achieved hSBA ≥1:8 against serogroups A, C, W135 and Y. At one month post vaccination, the percentages of subjects with hSBA≥1:8 were 98%-100% and 84%-96%, respectively.
Sedam dana nakon docjepljivanja, 98% - 100% ispitanika koji su prethodno cijepljeni cjepivom Menveo i 73% - 84% ispitanika koji su prethodno cijepljeni cjepivom ACWY-PS postigli su hSBA ≥1:8 protiv serogrupa A, C, W135 i Y. Mjesec dana nakon cijepljenja, postotci ispitanika s hSBA≥1:8 iznosili su 98% - 100% i 84% - 96%.
At 7 days post vaccination, 64% of subjects achieved hSBA ≥1:8 against serogroup A and 88% through 90% of subjects had bactericidal antibodies against serogroups C, W135 and Y. At one month post vaccination, 92% through 98% of subjects had hSBA ≥1:8 against serogroups A, C, W135 and Y. A robust immune response as measured by hSBA GMTs against all serogroups was also observed at 7 days (GMTs 34 through 70) and 28 days (GMTs 79 through 127) after a single dose vaccination.
Sedam dana nakon cijepljenja, 64% ispitanika postiglo je hSBA ≥1:8 protiv serogrupe A i 88% do 90% ispitanika imalo je baktericidna protutijela protiv serogrupa C, W135 i Y. Mjesec dana nakon cijepljenja, 92% do 98% ispitanika imalo je hSBA ≥1:8 protiv serogrupa A, C, W135 i Y. Snažan imunološki odgovor, mjeren kao hSBA GMTs protiv svih serogrupa, također je primijećen 7 dana (GMTs 34 do 70) i 28 dana (GMTs 79 do 127) nakon cijepljenja jednom dozom.
At 72 months
U 72. mjesecu
At 8 years, 81 of 207 patients originally treated with 40 mg Humira every other week were evaluated radiographically.
U 81 od 207 bolesnika koji su uzimali lijek Humira 40 mg svaki drugi tjedan učinjena je radiografska kontrola nakon 8 godina.
At 8 years, the survival rate was estimated to be 86.9% in the ACPH arm and 79.4% in the ACP arm, an absolute benefit of 7.4% (95% CI 4.9%, 10.0%).
Procijenjena stopa preživljenja nakon 8 godina iznosila je 86,9% u skupini liječenoj AC→PH kemoterapijom te 79,4% u skupini koja je primala AC→P kemoterapiju, što ukazuje na apsolutnu korist od 7,4% (95% CI 4,9%, 10,0%).
At 84 mg once daily dosing with eliglustat in PMs, it is predicted that concomitant use of moderate CYP3A inhibitors (e.g. erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine) would increase the Cmax and AUC0-24 of eliglustat 2.4- and 3.0-fold, respectively.
Pri dozi eliglustata od 84 mg jednom dnevno kod SM-a, predviđa se da će istovremena primjena umjerenih inhibitora CYP3A (npr. eritromicin, ciprofloksacin, flukonazol, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidin) povećati Cmax i AUC0-24 eliglustata 2,4 odnosno 3,0 puta.
At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP2D6 inhibitors (e.g. duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone) would increase eliglustat exposure approximately up to 4-fold.
Predviđa se da bi istovremena primjena umjerenih inhibitora CYP2D6 (npr. duloksetin, terbinafin, moklobemid, mirabegron, cinakalcet, dronedaron) povećala izloženost eliglustatu približno do 4 puta pri dozi od 84 mg eliglustata dva puta dnevno kod bolesnika koji nisu SM-i.
At 84 mg twice daily dosing with eliglustat in non-PMs, it is predicted that concomitant use of moderate CYP3A inhibitors (e.g. erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine) would increase eliglustat exposure approximately up to 3-fold.
Predviđa se da bi istovremena primjena umjerenih inhibitora CYP3A (npr. eritromicin, ciprofloksacin, flukonazol, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fozamprenavir, imatinib, cimetidin) povećala izloženost eliglustatu približno do 3 puta pri dozi eliglustata od 84 mg dva puta dnevno kod bolesnika koji nisu SM-i.
At 84 months the estimated overall survival is 86.4% (83, 90) vs.
Nakon 84 mjeseca, procijenjeno ukupno preživljenje iznosi 86,4% (83, 90) u odnosu na 83,3% (80,
At 96 weeks in the pooled Phase 3 C209 and C215 studies of treatment-naïve patients, in the rilpivirine+emtricitabine/tenofovir disoproxil fumarate arm the mean change from baseline in total cholesterol (fasted) was 2 mg/dL, in HDL-cholesterol (fasted) 4 mg/dL, in LDL-cholesterol (fasted)
U 96. tjednu, u objedinjenim ispitivanjima C209 i C215 faze 3 bolesnika koji prethodno nisu bili liječeni, u skupini koja je primala rilpivirin+emtricitabin/tenofovirdizoproksilfumarat srednja vrijednost promjene od početne vrijednosti kod ukupnog kolesterola (natašte) iznosila je 2 mg/dl, kod HDL-kolesterola (natašte) 4 mg/dl, kod LDL-kolesterola (natašte) -1 mg/dl, i kod triglicerida (natašte)